RespireRx Pharmaceuticals Inc (RSPI)

[drfreely]

I have to agree with you in regards investor relations. The public proclamations, when they do arrive are most often misleading. Last Fall, we were told a RD deal would arrive in thirty days, and that management were reviewing options in response to NASDAC delisting. Within a couple of months we were delisted, and when an RD deal finally arrived in the Spring, we discovered it had been sold for less than development cost. When the clinical director departed, we were told it was for "personal reasons." Then we were told to expect SA results by end of summer, then assured they'd be released in late October. I also think it especially cynical to conduct back-channel communications only thru ihubbers held hostage by CORX management and drugged by info tidbits for so long that they suffer from Stockholm syndrome.
If it ever did exist, the promise of ampakine technology has been undermined, perhaps permanently, by such poor communication choices. Why would any biotech analyst ever bother to cover us when fed such a long stream of misleading information, and pandering doubletalk. As for the investor, poor communication and even outright lies are overlooked as long as there is stock appreciation. When there is decimation, followed by long periods of stagnation, investors don't follow the stock so much as exhume it from time to time as you do, and examine it as one who owns a shrunken head, or monkey's paw might do.